Excelra Blog

Data Science To Empower
Life Science Innovation

Latest Stories

Featured Stories

July 09, 2020

Coronavirus Clinical Trials Landscape - Analysis Using Excelra’s COVID-19 Biomarker Database

The ongoing COVID-19 pandemic is continuing to spread rapidly across the globe. As of 30th June 2020, the World Health Organization (WHO) has reported over 10 million cases and half a million deaths across 188 countries. Current clinical research is focused on accelerating the development of drugs and vaccines for treatment of SARS-CoV-2 infection. In this scenario, identification and selection of the right biomarkers is of paramount importance and plays a critical role for optimizing clinical trial design and successful drug development. It is quite cumbersome to find the biomarker data which is often scattered across public literature and considerable efforts go into data annotation from numerous disparate and dispersed sources.


Excelra's COVID-19 Biomarker Database is an ‘Open-Access’ resource which is excerpted from our GOBIOM platform - the world’s largest biomarker intelligence database. COVID-19 Biomarker Database is a compilation of manually curated biomarkers from published clinical trials, evaluating potential drugs or biologics for the treatment of SARS-CoV-2. The database additionally includes information on FDA-NIH recommended BEST (Biomarkers, EndpointS and other Tools) classification of biomarkers, supported with direct links to the referenced literature. In the following sections, we present crucial statistics on the global COVID-19 clinical trial landscape with data and visualizations from the COVID-19 Biomarker Database.

Clinical Trials Analysis

Clinical Trials Characteristics

Out of the 2351 registered clinical trials on COVID-19, 785 clinical trials with biomarker information were included in the COVID-19 biomarker database. The included clinical trials comprised of 627 (80%) interventional studies and 158 (20%) observational studies.


Of the 785 clinical trials with biomarker information which are included in the database, majority biomarkers are proteomic followed by Scoring scale, Physiological, Cellular, Biochemical, Genomic and imaging biomarkers.


Figure 1: Biomarker count by type


Majority of the biomarkers included in the trials are utilized for assessing the Pharmacodynamic/Response for the drugs under investigation.


Figure 2: Numbers indicate clinical trial count

Clinical Trial Phase

Analysis of clinical trials in COVID-19 biomarker database suggest that majority of trials are in Phase II (52%) followed by phase III (28%), Phase I (14%) and Phase IV (6%).


Figure 3: No. of clinical trials by Phase. *Clinical trial counts represent clinical trials with biomarker information.

Study Population Size

Further analysis on the sample size included in the clinical trials reveals that majority of the trials (28%) recruit 100-500 patients in the clinical trials.


Figure 4: Study population distribution in clinical trials

Drugs/Therapies Investigated

Overall, 535 clinical trials were registered for testing the therapeutic benefits of potential drugs/vaccines, including 133 (25%) clinical trials for monotherapy and 404 (75%) clinical trials for combination therapy.


Figure 5: Numbers represent clinical trial counts

Research Landscape

Numerous clinical trials have been registered by the Industry/Academia/Research institutes in clinicaltrials.gov for evaluating Pharmacodynamic/Response for the drugs under investigation.


Below are the top contributors by no. of studies


Figure 6: Numbers represent clinical trial counts


Analysis of the data in COVID-19 biomarker database shows that the primary focus of the current clinical trial research is to evaluate Pharmacodynamic/Response for the drugs under investigation. Of the studies evaluating Pharmacodynamic/Response for the drugs, majority studies (75%) have included combination drug therapies. Given that most of the clinical trials (28%) include 101-500 patients in the study, many of these studies are likely to provide evidence on efficacy and safety of the investigated therapy.


It is noteworthy that our analysis was limited to clinical trials registered in clinicaltrials.gov.

Excelra’s COVID-19 Biomarker Database has been released in support of the ongoing global scientific efforts, aimed at developing safe and effective therapeutic options to treat the novel coronavirus disease.


Click here to access the database: https://www.excelra.com/covid-19-biomarker-database/

To schedule a Free GOBIOM Demo write to us at: marketing@excelra.com

Subscribe for Updates

Request Meeting

Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced. Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced.Lorem Ipsum is a simple dummy text used as a dummy text contents. Lorem ipsum will be replaced.

Submit Comment